FDA Does Not Approve Ivacaftor for Some Rare Mutations of Cystic Fibrosis
February 5, 2016
The U.S. Food and Drug Administration (FDA) has decided not to approve the use of ivacaftor (Kalydeco®) to treat people with cystic fibrosis ages 2 and older who have one of 23 rare CF mutations, known as “residual function” mutations.